1417342-72-3

Upstream product

• 1225439-73-5 tert-butyl 3-hydroxy-3-(o-tolyl)azetidine-1-carboxylate 
• 932-31-0 ortho-tolylmagnesium bromide 
• 1417342-71-2 tert-butyl 3-cyclopropylmethoxy-3-o-tolylazetidine-1-carboxylate 

Downstream Products

• 1417342-73-4 tert-butyl [(R)-2-(3-cyclopropylmethoxy-3-o-tolylazetidin-1-yl)-1-(4-methoxybenzyl)-2-oxoethyl]carbamate 

Relevant academic research and scientific papers

Development of a Kilogram-Scale Synthesis of a Novel MC1R Agonist

Herein, we report the kilogram-scale synthesis of CD08108, a novel MC1R agonist. This synthesis has been developed to produce the first batches of this compound for preclinical and clinical studies. Two amido couplings were used to synthesize the backbone

OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS

The present invention relates to the pharmaceutical field and in particular to the treatment of hypopigmentary pathologies and photosensitive dermatoses. More specifically, the invention relates to compounds that are agonists of the MC1R receptor and which exhibit reduced toxicity relative to the other compounds of the same class. These compounds have the general formula (I) below: in which: R1 represents a cyclopropylmethyl or a 4-hydroxybutyl group; R2 represents a hydrogen atom or a methyl group; and also the salts and enantiomers of the corresponding compounds of general formula (I).